Background/Objectives: Low-dose phthalate exposure acts as an adjuvant for immunoglobulin production and exacerbates atopic dermatitis (AD)-like lesions; however, research on orally administered di-(2-ethylhexyl) phthalate (DEHP)-mediated AD aggravation remains limited. This study evaluated the protective effects of crude saponins from red ginseng (CS) against DEHP-aggravated AD using a 2,4-dinitrochlorobenzene (DNCB)-induced male BALB/c mouse model. Methods: AD was induced by repeated topical DNCB application, followed by oral DEHP exposure with concurrent CS application at three doses (5, 15, and 50 mg/kg). Clinical severity scores, skin histopathology, organ indices, and serum allergic mediators were assessed. Results: DEHP exposure significantly increased erythema, edema, excoriation, epidermal/dermal thickening, and tissue eosinophil and mast cell infiltration. CS treatment markedly reduced clinical scores, eosinophil infiltration, and plasma histamine, serum immunoglobulin E (IgE), interleukin-5 (IL-5), and thymic stromal lymphopoietin (TSLP), suppressing Th2-biased systemic inflammation. Conclusions: These findings indicate that CS attenuates DEHP-exacerbated AD-like inflammation in a mouse model, potentially through modulation of Th2-associated allergic responses. Although further validation in human-relevant models is required, these results provide proof-of-concept evidence supporting the investigation of standardized red ginseng saponin preparations as potential adjunctive approaches for environmentally aggravated AD.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: